WO2015072724A1 - 광범위한 농도범위의 생체물질 농도 측정이 가능한 면역크로마토그래피 스트립 센서 - Google Patents
광범위한 농도범위의 생체물질 농도 측정이 가능한 면역크로마토그래피 스트립 센서 Download PDFInfo
- Publication number
- WO2015072724A1 WO2015072724A1 PCT/KR2014/010810 KR2014010810W WO2015072724A1 WO 2015072724 A1 WO2015072724 A1 WO 2015072724A1 KR 2014010810 W KR2014010810 W KR 2014010810W WO 2015072724 A1 WO2015072724 A1 WO 2015072724A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antigen
- line
- concentration
- antibody
- pad
- Prior art date
Links
- 239000012620 biological material Substances 0.000 title abstract description 9
- 238000003317 immunochromatography Methods 0.000 title abstract description 4
- 239000000427 antigen Substances 0.000 claims abstract description 155
- 102000036639 antigens Human genes 0.000 claims abstract description 151
- 108091007433 antigens Proteins 0.000 claims abstract description 151
- 238000000034 method Methods 0.000 claims abstract description 38
- 238000001514 detection method Methods 0.000 claims abstract description 29
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 75
- 102100032752 C-reactive protein Human genes 0.000 claims description 75
- 239000012528 membrane Substances 0.000 claims description 49
- 238000012360 testing method Methods 0.000 claims description 49
- 229940127121 immunoconjugate Drugs 0.000 claims description 17
- 239000002105 nanoparticle Substances 0.000 claims description 16
- 238000005206 flow analysis Methods 0.000 claims description 14
- 108010062374 Myoglobin Proteins 0.000 claims description 13
- 102000036675 Myoglobin Human genes 0.000 claims description 13
- 238000012545 processing Methods 0.000 claims description 13
- 238000010521 absorption reaction Methods 0.000 claims description 9
- 238000011088 calibration curve Methods 0.000 claims description 8
- -1 polyethylene Polymers 0.000 claims description 8
- 239000010931 gold Substances 0.000 claims description 7
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 6
- 239000004677 Nylon Substances 0.000 claims description 5
- 229910052737 gold Inorganic materials 0.000 claims description 5
- 229920001778 nylon Polymers 0.000 claims description 5
- 229920000728 polyester Polymers 0.000 claims description 5
- 239000000020 Nitrocellulose Substances 0.000 claims description 4
- 239000002033 PVDF binder Substances 0.000 claims description 4
- 239000004743 Polypropylene Substances 0.000 claims description 4
- 229920001220 nitrocellulos Polymers 0.000 claims description 4
- 229920001155 polypropylene Polymers 0.000 claims description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 claims description 4
- 239000004698 Polyethylene Substances 0.000 claims description 3
- 229920006393 polyether sulfone Polymers 0.000 claims description 3
- 229920000573 polyethylene Polymers 0.000 claims description 3
- 239000004695 Polyether sulfone Substances 0.000 claims description 2
- 238000012123 point-of-care testing Methods 0.000 abstract description 6
- 230000035945 sensitivity Effects 0.000 abstract description 4
- 239000000523 sample Substances 0.000 description 37
- 238000005259 measurement Methods 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 238000003556 assay Methods 0.000 description 13
- 239000002250 absorbent Substances 0.000 description 11
- 230000002745 absorbent Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 9
- 239000012530 fluid Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 229920002678 cellulose Polymers 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000000123 paper Substances 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- GNTDGMZSJNCJKK-UHFFFAOYSA-N divanadium pentaoxide Chemical compound O=[V](=O)O[V](=O)=O GNTDGMZSJNCJKK-UHFFFAOYSA-N 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000010955 niobium Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000010948 rhodium Substances 0.000 description 2
- 229910052707 ruthenium Inorganic materials 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 238000011546 CRP measurement Methods 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000005062 Polybutadiene Substances 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 229920002433 Vinyl chloride-vinyl acetate copolymer Polymers 0.000 description 1
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 208000037998 chronic venous disease Diseases 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZBKIUFWVEIBQRT-UHFFFAOYSA-N gold(1+) Chemical compound [Au+] ZBKIUFWVEIBQRT-UHFFFAOYSA-N 0.000 description 1
- 229910052735 hafnium Inorganic materials 0.000 description 1
- VBJZVLUMGGDVMO-UHFFFAOYSA-N hafnium atom Chemical compound [Hf] VBJZVLUMGGDVMO-UHFFFAOYSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910052758 niobium Inorganic materials 0.000 description 1
- GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical compound [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000580 poly(melamine) Polymers 0.000 description 1
- 229920005671 poly(vinyl chloride-propylene) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- VSZWPYCFIRKVQL-UHFFFAOYSA-N selanylidenegallium;selenium Chemical compound [Se].[Se]=[Ga].[Se]=[Ga] VSZWPYCFIRKVQL-UHFFFAOYSA-N 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54346—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
- G01N33/553—Metal or metal coated
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/795—Porphyrin- or corrin-ring-containing peptides
- G01N2333/805—Haemoglobins; Myoglobins
Definitions
- Immunochromatography strip sensor for measurement of biomaterial concentrations over a wide range of concentrations
- the present invention relates to an immunochromatographic strip sensor capable of measuring a concentration of a biomaterial in a wide range of concentrations and a method for measuring the concentration of a biomaterial in a wide range of concentrations using the sensor.
- C-react ive protein is a well-known acute inflammatory biomarker that consists of five repeats in the form of pent raxin and is synthesized in the liver when stimulated by interleukin-1 and interleukin-6. .
- CRP levels average 0.8 u g / mL, but when inflammation occurs, their levels increase above 100 mg / L.
- FDA recommends the measurement of CRP in inflammation and the determination of high sens i t ivi ty CRP (hs-CRP), a reliable biomarker and potential predictor of cardiovascular disease, in the concentration range of 20-500 u g / mL.
- concentration range required for its measurement is 1-10 y g / mL.
- the DIAgam XS Cardio NanoGold C-reactive protein (CRP) method can be measured in the range of 0.42-265 ug / mL using reagents from the DIAgam laboratory (Li l le, France).
- the DIAgam reagent measures the entire concentration range over a concentration range of 0.1-160 yg / mL using the step of diluting the sample and using the Olympus AU640 Biochemistry Analyzer.
- These methods use automated analyzers to provide accurate measurements, but require expensive equipment and skilled personnel to perform the analytical process.
- a method for detecting CRP with low cost, short analysis time and simple operation technique suitable for field display system has been proposed.
- microcropizidic chips have been extensively studied as a tool for measuring CRP.
- the microfluidic chip was able to detect CRP concentrations of 10 ng / mL for 3 minutes and CRP levels of 1 ng / mL or lower for 14 minutes.
- the lateral flow polymer chip had a dynamic range of 102 and had a detection limit of 2.6 ng / mL.
- LFA strip biosensors are one of the fastest, low cost and one step immunoassays (17).
- Several types of LFA based CRP test strips Although commercially available, the sandwich immunoassay has the disadvantage of not covering the range of CRP concentrations in human serum due to the hook effect resulting in false negative results due to very high concentrations of the analyte (18-19). ). For this reason, most commercial LFA strip sensors are used for the diagnosis of high sensitivity CRP (hsCRP) or cardiac CRP (cCRP).
- hsCRP high sensitivity CRP
- cCRP cardiac CRP
- “digital-style” or “barcode-style” assays using gold nanoparticles (AuNPs) as indicators can be used to count low concentrations of red lines in a test within 15 minutes.
- CRP is detected to provide a semi-quantitative lateral flow assay that predicts initial CVD risk or bacterial and viral infections.
- the LFA sensor used the multi-line measurement method to detect the same CRP, although the measurement objectives were different for each disease. There is a need for developing a one-stage immunosensor for CRP analysis that can cover a wide range of concentrations from 0 to 500 mg / L.
- LFA biosensors have important factors for evaluating the quality of rapid diagnostic sensors or on-site inspections such as ease of use, commercial accessibility and manufacturing costs (21).
- Triant VA Meigs JB, Gr inspoon SK. Journal of acquired immune deficiency syndromes 2009; 51: 268-73.
- the present inventors have tried to develop a biosensor capable of accurate concentration measurement even for a biological material having a wide concentration range.
- an antigen line (ant igen l ine) is added between the control line and the test line (in l) for a wide range of concentrations.
- the present invention was completed by experimentally confirming that the concentration of antigen can be measured accurately and quickly.
- Another object of the present invention is to provide a method for measuring the concentration of antigen in a wide range of concentrations using a lateral flow assay strip sensor.
- the present invention is a lateral flow assay strip sensor for measuring the concentration of the antigen in a wide range of concentration
- the lateral flow assay strip sensor is a sample pad, conjugate pad, membrane and absorbent pad in sequence A conjugated structure, wherein the conjugate pad includes a nanoparticle-detecting antibody conjugate to which nanoparticles and a detection antibody that binds the antigen are connected, and on the membrane, a test line from the conjugate pad toward the absorption pad.
- the antigen lines and the control lines are sequentially formed, the capture antibody binding to the antigen is fixed to the test line, the antigen is fixed to the antigen line, and the control antibody binds to the detection antibody.
- 2 car A lateral flow assay strip sensor is characterized in that the antibody is immobilized.
- the Lateral Flow Assay (LFA) strip sensor of the present invention includes a structure in which a sample pad, a conjugate pad, a membrane, and an absorption pad are sequentially connected. .
- the "sample pad” means a pad capable of diffusing flow by receiving a sample to be analyzed and is composed of a material having a porosity sufficient to contain and contain a sample to be analyzed.
- porous materials include fibrous paper; Microporous membranes of cellulose material, cellulose derivatives such as cellulose, salose acetate, nitrocellulose, fiberglass, naturally occurring cotton, fabrics such as nylon, or porous gels
- the present invention is not limited thereto.
- the "conjugate pad” is a pad containing a “nanoparticle-detecting antibody conjugate", which receives a sample diffused and moved from the sample pad and is connected to a detection antibody that binds nanoparticles and antigens.
- the conjugate pad like the sample pad, consists of a material capable of diffusion flow.
- the nanoparticles of the "nanoparticle-detecting antibody conjugate” included in the conjugate pad refer to nanoparticles that act as detectable labels.
- the nanoparticles are preferably nanoparticles of metal, for example gold (Au), silver (Ag), platinum (Pt), palladium (Pd), iridium (Ir), rhodium (Rh), Precious metals of ruthenium (Ru); Titanium (Ti), Zirconium (Zr), Hafnium (Hf), Vanadium (V), Niobium (Nb), Tantalum (Ta), Chromium (Cr), Molybdenum (Mo), Tungsten (W), Ruthenium (Ru), a transition metal of osmium (0s); Metals such as iron (Fe), nickel (Ni) and cobalt (Co); Metal oxides of magnesium oxide (MgO), titanium dioxide (Ti02), vanadium pentoxide (V205), zinc oxide (ZnO), and the like.
- the detection antibody refers to an antibody that specifically binds to the antigen to be analyzed, and means to include a fragment of the antibody if it has binding specificity.
- the detection antibody may be a monoclonal antibody or a polyclonal antibody, most preferably a monoclonal antibody.
- the binding of the nanoparticles to the detection antibody includes, but is not limited to, for example, ionic bonds, covalent bonds, metal bonds, coordination bonds, hydrogen bonds, and van der Waals bonds.
- the "membrane” in the sensor of the invention can be made of any of a variety of materials through which the sample material can pass.
- natural, synthetic, or synthetically modified, naturally occurring materials such as polysaccharides (eg, cellulose materials such as cellulose materials, paper, cellulose acetate and cellulose derivatives such as nitrocellulose) ; Polyether sulfones; Polyethylene; nylon; Polyvinylidene fluoride (PVDF); Polyester; Polypropylene; Silica; Inorganic materials homogeneously dispersed in a porous polymer matrix with polymers such as vinyl chloride, vinyl chloride-propylene copolymer and vinyl chloride-vinyl acetate copolymer, for example inactivated alumina, diatomaceous earth, MgS04, or other inorganic finely divided material ; Naturally occurring (eg cotton) and synthetic (eg nylon or rayon) cloth; Porous gels such as silica gel, agarose, dextran and gelatin; Polymer films
- the "hop pad” may be located adjacent to or near the end of the membrane.
- Absorbent pads generally receive fluid samples that travel through the entire membrane. The absorbent pad can help to promote capillary action and diffusion flow of the fluid through the membrane.
- the sensor of the present invention consists of the sample pad, the conjugate pad, the membrane and the hop pad being sequentially connected on the same support.
- the support may be formed of any material as long as it can support and transport the sample pad, the conjugate pad, the membrane, and the absorbent pad, but in general, the fluid of the sample diffused through the membrane does not leak through the support. It is preferred to be liquid impermeable.
- glass Polymeric materials such as, but not limited to, polystyrene, polypropylene, polyester, polybutadiene, polyvinylchloride, polyamide, polycarbonate, epoxide, methacrylate, polymelamine, and the like.
- test line test l ine
- antigen line antigen l ine
- control line control l ine
- a capture antibody that binds to the antigen is fixed to the "test line”.
- the antigen is fixed to the "antigen line”.
- the antigen immobilized on the antigen line is immobilized via a capture antibody immobilized on the membrane. Rather than immobilizing the antigen directly on the membrane in the antigen line, the antigen can be exposed in the proper direction to facilitate binding with the nanoparticle-detecting antibody. Can improve.
- a secondary antibody that binds to the detection antibody is immobilized on the "contain line".
- the secondary antibody in the control line binds to the nanoparticle-detecting antibody or nanoparticle-detecting antibody-antigen complex to generate a detection signal for it.
- the term “antigen” refers to a substance to be analyzed for concentration or presence, and includes, for example, proteins, peptides, microorganisms, amino acids, nucleic acids, hormones, steroids, vitamins, drugs, bacteria, viral particles, and the like. One is not limited thereto.
- the antigen is most preferably a C-react ive protein (CRP).
- sample refers to a biological substance suspected of containing the antigen to be analyzed.
- blood interstitial fluid, saliva, eyepiece fluid, cerebrospinal fluid, sweat, urine, milk, ascites, mucus, nasal fluid (nasal fizid), hemoptysis, arterial blood, abdominal fluid, vaginal fluid, menstrual discharge, amniotic fluid, And semen, and may be derived from any biological source, such as a physiological fluid.
- the present invention provides a method for measuring the concentration of antigen in a wide range of concentrations using a lateral flow assay strip sensor,
- the lateral flow analysis strip sensor includes a structure in which a sample pad, a conjugate pad, a membrane, and an absorption pad are sequentially connected.
- the conjugate pad includes a nanoparticle-detecting antibody conjugate to which a nanoparticle and a detection antibody that binds the antigen are connected.
- Test lines, antigen lines and control lines are sequentially formed on the membrane from the conjugate pad toward the absorbent pad,
- test line is fixed to the capture antibody that binds to the antigen
- the antigen is fixed to the antigen line
- a secondary antibody that binds to the detection antibody is immobilized, and the method includes the following steps:
- step (c) performing steps (a) and (b) on samples containing antigens to be analyzed at different concentrations than in step (a);
- step (f) measuring signals generated in the test line, antigen line and control line; And (g) calculating the concentration of the antigen of unknown concentration using the measured signal value and the calibration curve of step (d).
- the present invention compares the signal value measured in the antigen line with the signal value measured in the control line, so that the signal value of the antigen line can Selecting a lower value among the calculated antigen concentration values when the signal value is larger than the signal value, and selecting a larger value among the calculated antigen concentration values when the signal value of the antigen line is smaller than the signal value of the line. It provides a method characterized in that.
- the signal in the test line is obtained with a bell shaped signal intensity curve because of the hook effect.
- the signal intensity of the test line increases as the concentration of the analyte antigen increases, and decreases again at a concentration higher than the threshold to form a bell-shaped curve.
- the signal strength produced by one sample measurement may indicate two different concentration results (see panel B of FIG. 5).
- the controls were compared for signal intensities of lines and antigen lines. Under optimal conditions, the signal intensity of the control line will be lower than that of the antigen line for samples with relatively low antigen concentrations. It shows a signal strength pattern that is lower than the strength. This phenomenon can be used to accurately measure the concentration of antigens in a wide range of concentrations in biological samples.
- the concentration range of the antigen that can be analyzed in the method of the present invention is 1 ng / mL-500 y g / mL.
- the present invention relates to an immunochromatographic strip sensor capable of measuring a concentration of a biomaterial in a wide range of concentrations and a method for measuring the concentration of a biomaterial in a wide range of concentrations using the sensor.
- the detection method using the sensor of the present invention accurately measures the concentration of antigen in a wide range of concentrations. It can be measured and can be implemented at low cost, speed and simplicity, making it suitable for P0CT (point of care test) where rapid and sensitive sensitivity is required.
- FIG. 1 is a schematic diagram of an LFA strip sensor into which an antigen is introduced.
- Panel A shows the structure
- panel B shows the detection principle
- panel C shows the data processing process.
- Figure 2 is a result of comparing the signal intensity measured l g / mL CRP between the direct binding of the CRP to the pre-treated antibody on the antigen line and PEG-CRP binding.
- Panel A is an image and
- Panel B is a graph. 3 shows the result of comparing the signal intensity of the antigen line by the type of pre-bound antibody.
- Panel A of FIG. 5 is an image of measuring CRP of various concentrations.
- Panel B is the result of plotting the signal intensity of three lines of a test line, an antigen line, and a control line in log unit.
- Panel C is the measurement result after processing the data.
- Figure 6 shows the results of testing 50 clinical samples 10 times dilution.
- Panel A is an image and Panel B is a graph.
- Serum (90R-100), surfactant 10G (95R-103), and bovine serum albumin (BSA) without CRP were purchased from Fitzerald Industries International (Acton, Mass., USA).
- CRP was purchased from Wako Chemicals (309-51191; Osaka, Japan), and anti-CRP polyclonal antibodies and monoclonal antibodies were obtained from Abeam Inc. (Cambridge, MA, USA).
- Nitrocellose membranes were purchased from Millipore (HFB02404; Billerica, Mass., USA). Sample pads (P / N BSP-133-20) and absorbent pads are available from Pall Co. (Port Washington, NY, USA). Interpad (Fusion5 8151-6621) was purchased from Whatman (Kent, UK).
- Each gold colloidal solution is BB
- PBS (1 mg / mL concentration) 10 with anti-CRP antibody was added to the mixture of 1 mL of 20 nm AuNP colloid and borate complete solution (0.1 M, H 8.5). After 30 minutes of incubation at silver phase, 0.1 mL of PBS containing 10 mg / mL of BSA was added to the solution to block the AuNP surface. After incubation at 4 ° C. for 60 minutes, the mixture was centrifuged for 15 minutes at 10 ° C. at 12,000 rpm using HANIL microcentr i fuge (micro 17TR; Quasar Instruments, Colorado Springs, Co., USA).
- the LFA sensor consists of four components: sample pad, conjugate pad, nitrocell membrane and absorbent pad. Most components are fixed on a conventional backing card, which typically consists of an inert plastic such as polyester. Immobilize capture antibody and CRP or PEG-CRP or capture antibody, and contacts in different regions on NC membranes (0.25 cm x 30 cm) using a human dispenser (DCI100; Zeta Corporation, yunggi-do, South Korea) Antigen (1 mg / mL) in the antigen line was immobilized in the cell at an amount of 1 yL / cm to the rose membrane, followed by CRPCl mg / mL) antigens were immobilized thereon.
- a human dispenser DCI100; Zeta Corporation, yunggi-do, South Korea
- the loaded membrane was dried for 1 hour in a temperature & humid chamber at 28 ° C. After drying the NC membrane, the membrane was cut using a cutter into strips of 3.8-mm-width, concentrated 2X AuNP-
- the antibody conjugate 12 is incubated on a conjugate pad (0.75 cm X 0.38 cm) and used at a Temperature '& humid chamber (Hanyang Scientific Equipment Co., Ltd, Korea) at 28 ° C. and 25% humidity. Sequentially dried An absorbent pad (1.5 cm ⁇ 0.38 cm) was attached to the top of the strip, and the sample pad (1.5 cm ⁇ 0.38 cm) was a sticky plastic backing (6) containing an NC membrane with immobilized antibody and absorbent pad. cm x 0.38 cm), assembled sequentially, each segment overlapping each other by 1.5 mm to facilitate solution migration during the analysis process.
- Capture antibodies and myoglobin antigen controls in different regions on the NC membrane (0.25 cm ⁇ 30 cm) were immobilized using a dispenser (DCI100; Zeta Corporation, Kyunggi-do, South Korea).
- the control line and the test line fixed each capture antibody (lmg / mL) to the cell membrane in an amount of 1 yL / cm, and fixed the antigen line between the two lines.
- the capture antibody (1 mg / mL) was immobilized on the cell in the amount of 1 yL / cm to the membrane, followed by the myoglobin (0.5 mg / mL) antigen. bracket The interval between regions was about 3 mm.
- the loaded membrane was dried at 37 ° C for 1 hour in a Temperature & humid chamber. After drying the NC membrane, the membrane was cut using a cutter into strips of 3.8-mm-width. Concentrated 3X AuNP-antibody conjugates were incubated on the conjugate pad (1 cm X 0.38 cm), using a Temperature & humid chamber (Hanyang Sci ent ific Equipment Co., Ltd, Korea) at 37 ° C and Stored after drying under 20% humidity. An absorbent pad (1.5 cm X 0.38 cm) is attached to the top of the strip, and the sample pad (1.5 cm X 0.38 cm) is a sticky plastic backing (6 cm X 0.38) containing an NC membrane with immobilized antibody and absorbent pad cm) were assembled sequentially. Each segment was overlapped with each other by 2 mm to facilitate solution migration during the analysis.
- Myoglobin solutions with varying concentrations were prepared using human serum without myoglobin.
- the prepared sample solution was incubated on the LFA sensor. Images were acquired using a ChemiDoc TM XRS + imaging system (Bio-Rad), followed by measurement of color intensity using Imagel ab TM 4.0 software (Bio-Rad).
- Serum samples of 50 patients were obtained from Kyungpook National University Hospital. The patient was given a detailed explanation of the study protocol and then consented. Blood samples were taken using a venipuncture in a tube containing lithium heparin antihypertensives (S-Monovette, Numbrecht, Germany). Next, the blood sample Cells in blood were removed by centrifugation for 15 minutes with 100xg. The collected samples were measured at a concentration of HITACHI 7180 and then stored at -80 ° C until further analysis of the plasma portion. Samples were diluted 10-fold with serumol containing no CRP before measurement. Experimental Results and Discussion
- the LFA strip sensor consists of a test line (test l ine), an antigen line (ant igen l ine) and a control line (control l ine), respectively, from the sample injection direction (Panel A of FIG. 1). Incubation of the serum sample onto the sample pad causes the solution to contact the sample pad and then wet the sample pad, the conjugation pad, and the NC membrane in the horizontal direction, respectively. Initially a sandwich reaction occurs between the antigen and the AuNP-monoclonal antibody conjugate complex in the antibody attached to the test line in the test line, and the AuNP-antibody conjugate, which is not reacted in the test line, is placed on the NC membrane in the antigen line. Bind to immobilized CRP antigen.
- the antigen lines When analyzing low concentrations of antigen, the antigen lines show the highest signal intensity, whereas when analyzing high concentrations of antigens, the antigen lines show very low signal strength or have no signal strength at all.
- the control line is used as a region to respond to the gold labeled monoclonal antibody.
- the overall reaction is shown in panel B of FIG. 1.
- the results measured at different antigen concentrations are shown by applying the data processing procedure (Panel C in FIG. 1).
- the test line the first location where the sample meets the AuNP complex, shows a red signal when the AuNP-antibody conjugate-antigen complex bound to the CRP antigen binds to an anti-CRP polyclonal antibody immobilized on the NC membrane. .
- an antigen line was introduced to use the correlation of the test line, the antigen line and the control line.
- the antigen line produced signals of different aspects depending on the concentration of antigen in the sample.
- the antigen line shows the highest signal value as opposed to the signal shown in the test line when the antigen concentration is zero.
- the signal intensity of the antigen line tended to decrease gradually as the concentration of antigen increased.
- the signal intensity of the test line increased gradually with the concentration. Indicated.
- the two lines did not show a red signal at a concentration of 500 ug / mL (Panel A in FIG. 5).
- the AuNP conjugate-antibody (Ab) -antigen (Ag) complex reacts with the capture antibody in the form of a sandwich assay, while the unreacted AuNP conjugate-antibody (Ab) is upwards along the NC membrane. Move and bind to the antigen in the antigen line. Binding affinity with CRP immobilized on the NC membrane was also reduced if excess antigen was first bound to capture antibodies in the test line before forming the AuNP conjugate -Ab ⁇ Ag complex. As a result, AuNP-conjugates in which the antigens contained high concentrations of antigens did not show the signal intensity of both the test and antigen lines because the immunoassay reaction was suppressed. It showed the highest signal because it binds to the gate-antigen complex.
- the most important factor for the manufacture of strip sensors is the immobilization of CRP in the antigen line.
- the inventors first immobilized the capture antibody in the antigen line to aid in the direction and stabilization of the CRP and then added the CRP thereto.
- CRP was immobilized directly on the NC membrane, there was no reaction between the immobilized antigen and the AuNP conjugate antibody.
- CRP was PEGylated using NHS-PEG to avoid this drawback in anticipation of CRP degradation.
- antigen lines bound to PEGylated CRP showed no signal (FIG. 2).
- the product was used.
- a monoclonal antibody was used as the detection antibody in the AuNP-detecting antibody conjugate to increase the efficiency of competition reaction in the antigen line.
- the detection antibody is used as a monoclonal antibody in the case of Detect i on ant i body graph, and in the case of Test ant i body l (Test l) and Test ant i body 2 (Test 2) It is the result when it uses for a polyclonal antibody.
- the detection antibody was used as a polyclonal antibody, it was confirmed that a signal was not decreased and a constant signal was maintained according to the CRP concentration to be measured differently from when using a monoclotal antibody.
- Panel C of FIG. 5 shows the results of measuring various concentrations of CRP through data processing.
- the experimental results above show that the sensor of the present invention can also measure CRP concentration levels between 105 and 106.
- a detection limit LOD, bl ank signal + 3 standard deviations
- This value means that we can develop a sensor that can measure 1.07 (ng / mL CRP concentration) as the highest concentration. 4. Measurement of Clinical Samples
- a method for measuring myoglobin which is one of myocardial infarction biomarkers, was used in the CRP to prove that it is applicable to all general antigens in addition to the measured CRP.
- the measurement lines, antigen lines and controls in myoglobin showed the same tendency as those determined in the CRP lines, and the results were analyzed using the same method as the method performed in the CRP.
- the result was a perfect linearity in the concentration range between 1 ng / mL and 500 ug / mL.
- the myoglobin measurement results of FIGS. 7 and 8 confirmed that the measurement method claimed in the present invention can be applied to various antigens. conclusion
- the present invention has developed a lateral flow immune sensor with multiple lines consisting of one strip capable of measuring a wide range of concentrations of CRP.
- the LFA sensor of the present invention analyzes the CRP concentration in the range of 1 ng / mL-500 u / mL in 10 minutes. could finish.
- the detectable concentration range was 0.67 ng / mL-1.02 mg / mL, which is the widest range that can be measured using the LFA strip sensor (approximately 106 times).
- the structure of the sensor consists of membranes and pads which are relatively inexpensive and light in manufacturing and processing, multi-line LFA systems are particularly advantageous for the development of suitable field inspection devices.
- the sensor of the present invention can be easily different and has a wide range of dynamic range, it is possible to detect CRP with high sensitivity and simple, as well as to accurately diagnose the degree of inflammation and the type of disease of the patient.
- myoglobin measurement resulted in almost the same measurement results as CRP.
- the antigens applicable to the present invention are not limited to CRP, but are capable of sandwich immunity and have two antibody pairs. It has been confirmed that it can be applied widely.
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Inorganic Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201480061733.4A CN105723220A (zh) | 2013-11-12 | 2014-11-11 | 能够测定广泛浓度范围的生物物质浓度的免疫层析条状传感器 |
US15/036,340 US20160291010A1 (en) | 2013-11-12 | 2014-11-11 | Immunochromatography strip sensor capable of measuring biomaterial concentration over broad concentration range |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2013-0136906 | 2013-11-12 | ||
KR20130136906 | 2013-11-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015072724A1 true WO2015072724A1 (ko) | 2015-05-21 |
Family
ID=53057609
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/010810 WO2015072724A1 (ko) | 2013-11-12 | 2014-11-11 | 광범위한 농도범위의 생체물질 농도 측정이 가능한 면역크로마토그래피 스트립 센서 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20160291010A1 (ko) |
KR (1) | KR101702117B1 (ko) |
CN (1) | CN105723220A (ko) |
WO (1) | WO2015072724A1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105891510A (zh) * | 2016-04-08 | 2016-08-24 | 四川新健康成生物股份有限公司 | 一种crp免疫荧光层析检测用包被膜、试纸条及其使用方法 |
CN114113614A (zh) * | 2021-12-02 | 2022-03-01 | 西北农林科技大学 | 一种单宁酸免疫网络及盐酸克伦特罗试纸条检测方法 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017052285A1 (ko) * | 2015-09-23 | 2017-03-30 | 한양대학교 에리카산학협력단 | 표면-증강 라만 산란 기반의 고감도 측면유동 면역분석용 스트립 및 이를 이용한 검출방법 |
KR101854240B1 (ko) * | 2016-05-18 | 2018-06-14 | 광주과학기술원 | 후크 효과가 없는 면역크로마토그래피 스트립 센서 |
CN106053794A (zh) * | 2016-06-30 | 2016-10-26 | 厦门宝太生物科技有限公司 | 一种用于准确检测待测物的试剂卡、试剂盒和用途 |
CN106226516B (zh) * | 2016-07-01 | 2018-06-29 | 安邦(厦门)生物科技有限公司 | 一种双曲线定标定量免疫层析检测方法 |
US20200340986A1 (en) * | 2017-10-31 | 2020-10-29 | Robert S. Gold | Test Strip to Identify Insect and Arachnid Ectoparasites |
KR102046556B1 (ko) * | 2017-11-20 | 2019-11-19 | 주식회사 제트바이오텍 | 고농도 검체 내 표적물질 정량화가 가능한 광범위 체외 진단 키트 |
CA3088126A1 (en) * | 2018-01-27 | 2019-08-01 | Becton, Dickinson And Company | Multiplex lateral flow assay for differentiating bacterial infections from viral infections |
CA3088124A1 (en) * | 2018-01-27 | 2019-08-01 | Becton, Dickinsion And Company | Multiplex lateral flow assay for differentiating bacterial infections from viral infections |
KR102133752B1 (ko) * | 2018-04-06 | 2020-07-16 | 바디텍메드(주) | 측방 유동 분석 스트립 |
CN110806477A (zh) * | 2018-08-06 | 2020-02-18 | 国家纳米科学中心 | 一种病原菌检测试纸条、传感器及其应用 |
KR102352617B1 (ko) * | 2019-12-26 | 2022-01-19 | 프리시젼바이오 주식회사 | 다중 면역 분석용 검사 스트립 제조 방법 및 이를 이용하여 제조된 검사 스트립 |
WO2022049437A1 (en) * | 2020-09-04 | 2022-03-10 | 3M Innovative Properties Company | Chromatographic reader devices for biodetection |
KR20220138823A (ko) | 2021-04-06 | 2022-10-13 | 고려대학교 산학협력단 | 코로나 19 바이러스 항체 검출용 측면유동면역분석 스트립 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100128550A (ko) * | 2009-05-28 | 2010-12-08 | 주식회사 인포피아 | 금 이온의 환원에 의한 측방유동 분석에서의 신호 증폭 방법 및 이를 이용한 측방유동 분석 디바이스 |
KR20120132249A (ko) * | 2011-05-27 | 2012-12-05 | 아주대학교산학협력단 | 정량분석이 가능한 측방 유동 검정 스트립 |
KR20130037647A (ko) * | 2011-10-06 | 2013-04-16 | 한국생명공학연구원 | 한 번의 시료 주입으로 순차적인 반응 조건의 변화가 가능한 멤브레인 센서 |
KR20130051429A (ko) * | 2011-11-09 | 2013-05-20 | (주)아이엠 | 골다공증 및 골회전율 진단 스트립 |
KR20130101071A (ko) * | 2010-09-30 | 2013-09-12 | 세키스이 메디칼 가부시키가이샤 | 면역 크로마토그래피용 테스트 스트립 및 그의 제조 방법 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030059951A1 (en) * | 2001-08-14 | 2003-03-27 | Frushour Susan L.M. | Maternal status testing in animals |
US7781172B2 (en) * | 2003-11-21 | 2010-08-24 | Kimberly-Clark Worldwide, Inc. | Method for extending the dynamic detection range of assay devices |
KR100639776B1 (ko) * | 2004-01-05 | 2006-10-27 | 바이오메드포토닉스 주식회사 | 측방 유동 정량 검정 방법 및 이를 위한 스트립과 레이저유발 표면형광 검출 장치 및 소형 스캐너 |
US7439079B2 (en) * | 2005-04-29 | 2008-10-21 | Kimberly-Clark Worldwide, Inc. | Assay devices having detection capabilities within the hook effect region |
FR2890173B1 (fr) * | 2005-08-23 | 2008-02-22 | Vedalab Sa | Dispositif de determination d'un analyte dans un echantillon liquide par un test sandwich et un test de competition |
EP1933140B1 (en) * | 2006-12-11 | 2011-08-17 | AraGen Biotechnology Co. Ltd. | Antibody detection method involving an oligonucleotide enhanced collodial gold signal |
KR101140029B1 (ko) * | 2010-02-23 | 2012-06-21 | 한국식품연구원 | 항원고정화 면역형광 슬라이드의 제조방법 및 그에 의해 제조되는 면역형광 슬라이드 |
FR2967497B1 (fr) * | 2010-11-17 | 2014-12-12 | Biomerieux Sa | Dispositif et procede pour immunoessais |
US20120258866A1 (en) * | 2011-04-05 | 2012-10-11 | Full Spectrum Genetics, Inc. | Multi-dimensional selection of protein mutants using high throughput sequence analysis |
CN104714008B (zh) * | 2015-02-04 | 2016-08-17 | 上海交通大学 | 一种免疫层析试纸条及其制作方法与检测方法 |
-
2014
- 2014-11-11 US US15/036,340 patent/US20160291010A1/en not_active Abandoned
- 2014-11-11 WO PCT/KR2014/010810 patent/WO2015072724A1/ko active Application Filing
- 2014-11-11 CN CN201480061733.4A patent/CN105723220A/zh active Pending
- 2014-11-12 KR KR1020140156838A patent/KR101702117B1/ko active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100128550A (ko) * | 2009-05-28 | 2010-12-08 | 주식회사 인포피아 | 금 이온의 환원에 의한 측방유동 분석에서의 신호 증폭 방법 및 이를 이용한 측방유동 분석 디바이스 |
KR20130101071A (ko) * | 2010-09-30 | 2013-09-12 | 세키스이 메디칼 가부시키가이샤 | 면역 크로마토그래피용 테스트 스트립 및 그의 제조 방법 |
KR20120132249A (ko) * | 2011-05-27 | 2012-12-05 | 아주대학교산학협력단 | 정량분석이 가능한 측방 유동 검정 스트립 |
KR20130037647A (ko) * | 2011-10-06 | 2013-04-16 | 한국생명공학연구원 | 한 번의 시료 주입으로 순차적인 반응 조건의 변화가 가능한 멤브레인 센서 |
KR20130051429A (ko) * | 2011-11-09 | 2013-05-20 | (주)아이엠 | 골다공증 및 골회전율 진단 스트립 |
Non-Patent Citations (1)
Title |
---|
OH ET AL.: "A three-line lateral flow assay strip for the measurement of C-reactive protein covering a broad physiological concentration range in human sera", BIOSENSORS AND BIOELECTRONICS, vol. 61, 14 May 2014 (2014-05-14), pages 285 - 289, XP055188391, DOI: doi:10.1016/j.bios.2014.04.032 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105891510A (zh) * | 2016-04-08 | 2016-08-24 | 四川新健康成生物股份有限公司 | 一种crp免疫荧光层析检测用包被膜、试纸条及其使用方法 |
CN114113614A (zh) * | 2021-12-02 | 2022-03-01 | 西北农林科技大学 | 一种单宁酸免疫网络及盐酸克伦特罗试纸条检测方法 |
CN114113614B (zh) * | 2021-12-02 | 2023-09-01 | 西北农林科技大学 | 一种单宁酸免疫网络及盐酸克伦特罗试纸条检测方法 |
Also Published As
Publication number | Publication date |
---|---|
KR101702117B1 (ko) | 2017-02-03 |
US20160291010A1 (en) | 2016-10-06 |
CN105723220A (zh) | 2016-06-29 |
KR20150054699A (ko) | 2015-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101702117B1 (ko) | 광범위한 농도범위의 생체물질 농도 측정이 가능한 면역크로마토그래피 스트립 센서 | |
CN106872420B (zh) | 一种时间分辨荧光定量检测尿微量白蛋白的试剂盒及方法 | |
US8093057B2 (en) | System for quantitative measurement of glycohemoglobin and method for measuring glycohemoglobin | |
KR920009420B1 (ko) | 고체상 분석장치 및 이를 이용하는 방법 | |
KR101280650B1 (ko) | 프로존 현상 검출 방법, 분석 방법, 프로존 현상 검출 장치 및 분석 장치 | |
JP2001337065A (ja) | 電気化学メンブレンストリップバイオセンサー | |
JP2008537145A (ja) | 半定量的免疫クロマトグラフ装置 | |
KR102133752B1 (ko) | 측방 유동 분석 스트립 | |
KR20090006999A (ko) | 당화헤모글로빈의 정량분석을 위한 시스템 및 이를 이용한당화헤모글로빈 측정 방법 | |
WO1999053318A1 (fr) | Procedes de detection d'anticorps et dispositif de detection d'anticorps | |
US20210033605A1 (en) | Lateral flow immunoassay strip device | |
KR101854240B1 (ko) | 후크 효과가 없는 면역크로마토그래피 스트립 센서 | |
EP1293780B1 (en) | Specific binding analysis method | |
Gonzalez et al. | Thread-paper, and fabric enzyme-linked immunosorbent assays (ELISA) | |
US20230333118A1 (en) | Immunoassay analyzer, immunoassay kit and method for detecting analyte in liquid sample | |
KR20160120675A (ko) | 래피드 정량 진단 키트 | |
JP3920741B2 (ja) | 物質の検出試薬及び検出方法 | |
JP2009192222A (ja) | 免疫学的測定方法 | |
EP3906113A1 (en) | Capture flow assay device and methods | |
WO2016014832A1 (en) | Biomarkers for assessment of preeclampsia | |
WO2021137387A1 (ko) | 정전 용량 센서를 이용한 면역 분석 검사 스트립 | |
JP2008180543A (ja) | 分離デバイス、血液成分測定デバイス、血液成分測定システム、分離機能物質、血液成分測定方法、および分離方法。 | |
Jonsson-Niedziółka | Suchanat Boonkaew, Katarzyna Szot-Karpinska, Joanna Niedziółka-Jonsson, Barbara Pałys b | |
Yu et al. | Platinum nanozyme-mediated temperature sensor for sensitive photothermal immunoassay of YKL-40 under near-infrared light | |
WO2023030561A1 (en) | Kit and method for simultaneous electrochemical determination of at least two protein analytes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14861540 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15036340 Country of ref document: US |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 19/08/2016) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14861540 Country of ref document: EP Kind code of ref document: A1 |